Hypertrofische cardiomyopathie

Klinische les
19-02-2019
Beau van Driel, Folkert W. Asselbergs, Rudolf A. de Boer, Albert C. van Rossum, J. Peter van Tintelen, Jolanda van der Velden en Michelle Michels

Dames en Heren,

De klinische presentatie, het beloop en de prognose van hypertrofische cardiomyopathie zijn zeer heterogeen. Voor het herkennen van patiënten met deze erfelijke hartziekte en hun familieleden en voor de juiste behandeling is kennis van de verschillende uitingsvormen en het klinische beloop vereist. In deze klinische les beschrijven wij de verschillende uitingsvormen van hypertrofische cardiomyopathie.

Hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. Its prevalence is estimated between 1:500 and 1:200. HCM is defined by left ventricular hypertrophy (wall thickness ≥ 15 mm) in absence of abnormal loading conditions such as hypertension. It is caused by mutations in cardiac sarcomere protein genes and inheritance is autosomal dominant. HCM is heterogeneous in terms of its clinical presentation, progression and prognosis, ranging from absence of symptoms in genotype-positive individuals to severe left ventricular hypertrophy, sudden cardiac death and end-stage heart failure at young age. Timely identification of HCM patients and initiation of proper treatment requires knowledge of the various manifestations of HCM. We describe the case of a 60-year-old female HCM patient and the four clinical stages of HCM with corresponding complications and treatment options.

Conflict of interest and financial support: potential conflicts of interest have been reported for this article. F.W. Asselbergs, J.P. van Tintelen and J. van der Velden received grants from CVON DOSIS during the conduct of the study. ICMJE forms provided by the authors are available online along with the full text of this article.